Anti-neural antibodies in leprosy sera: further characterization of the antigens.
Sera or plasmas from 129 leprosy patients were tested by immunoblotting for antibodies that bound to proteins in a Triton-insoluble fraction enriched in neural intermediate filaments (IF fraction) from human or bovine spinal cord. Sixty samples (47%) showed positive staining of proteins at 35 kDa, 42 kDa or both. The presence of these antibodies appeared to be evenly distributed across the spectrum of disease. The frequency of these antibodies in samples from 12 healthy Ethiopians was similar to that in the leprosy group. Similar antibodies were found in only three of 28 samples from U.S. patients with neurologic diseases and in seven of 35 normal U.S. sera. Sera from U.S. tuberculosis patients stained multiple bands in the 50-30 kDa region of the blots; 11 of 16 stained bands corresponding to the 35 kDa or 42 kDa bands along with a number of other bands in this region. The 35 kDa and 42 kDa antigens do not appear to be breakdown products of neural filaments or glial fibrillary acidic protein, since antibodies to these proteins do not react with the 35 kDa or 42 kDa antigen. Further, the staining pattern with the leprosy sera is unchanged following Ca2+-mediated proteolysis of the IF-enriched fraction. The two antigens differ from one another in isoelectric point: the pI of the 35 kDa antigen is 5.9, and the pI of the 42 kDa antigen is 4.8. Staining of the immunoblots with antibodies against a number of known neural antigens failed to identify the 35 kDa and 42 kDa antigens. The 42 kDa antigen appears to be a component of axolemma, since 42 kDa-positive leprosy sera stained a protein with identical migration in preparations of bovine peripheral nervous system and human central nervous system axolemma. In some sera, antibodies reacting with the 35 kDa antigen were adsorbed by D-O bovine serum albumin, a synthetic analogue of the terminal disaccharide portion of the phenolic glycolipid 1 of Mycobacterium leprae. Antibodies to the 42 kDa antigen were not removed by this treatment.
Benjamins
J A
JA
Department of Neurology, Wayne State University, School of Medicine, Detroit, MI 48201.
Callahan
R E
RE
Runft
D
D
Gerras
G
G
Lefford
M J
MJ
D000906:Antibodies / Q000032:analysis*; D000941:Antigens / Q000276:immunology*; D000942:Antigens, Bacterial; D005455:Fluorescent Antibody Technique; D006017:Glycolipids / Q000276:immunology; D006801:Humans; D015151:Immunoblotting; D007382:Intermediate Filaments / Q000276:immunology; D007918:Leprosy / Q000097:blood / Q000276:immunology*; D008970:Molecular Weight; D009166:Mycobacterium leprae / Q000276:immunology; D013116:Spinal Cord / Q000276:immunology*; D013194:Staining and Labeling
D000906:Antibodies; D000941:Antigens; D000942:Antigens, Bacterial; D006017:Glycolipids; C045169:phenolic glycolipid I, Mycobacterium leprae